Compile Data Set for Download or QSAR
Report error Found 152 Enz. Inhib. hit(s) with all data for entry = 7513
TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199038BDBM199038(US9221832, 102)
Affinity DataIC50: 2.20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199025BDBM199025(US9221832, 89)
Affinity DataIC50: 3.20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198943BDBM198943(US9221832, 7)
Affinity DataIC50: 3.5nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199023BDBM199023(US9221832, 87)
Affinity DataIC50: 4.60nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199010BDBM199010(US9221832, 74)
Affinity DataIC50: 4.70nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199064BDBM199064(US9221832, 128)
Affinity DataIC50: 5.60nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199046BDBM199046(US9221832, 110)
Affinity DataIC50: 6.70nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198970BDBM198970(US9221832, 34)
Affinity DataIC50: 7.40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199050BDBM199050(US9221832, 114)
Affinity DataIC50: 7.60nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199045BDBM199045(US9221832, 109)
Affinity DataIC50: 9nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199028BDBM199028(US9221832, 92)
Affinity DataIC50: 9nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199009BDBM199009(US9221832, 73)
Affinity DataIC50: 9.90nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199030BDBM199030(US9221832, 94)
Affinity DataIC50: 11nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198941BDBM198941(US9221832, 5)
Affinity DataIC50: 12nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199066BDBM199066(US9221832, 131)
Affinity DataIC50: 14nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199033BDBM199033(US9221832, 97)
Affinity DataIC50: 15nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199019BDBM199019(US9221832, 83)
Affinity DataIC50: 15nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199021BDBM199021(US9221832, 85)
Affinity DataIC50: 15nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198942BDBM198942(US9221832, 6)
Affinity DataIC50: 16nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199039BDBM199039(US9221832, 103)
Affinity DataIC50: 16nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198985BDBM198985(US9221832, 49)
Affinity DataIC50: 17nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199002BDBM199002(US9221832, 66)
Affinity DataIC50: 20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199015BDBM199015(US9221832, 79)
Affinity DataIC50: 21nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199069BDBM199069(US9221832, 134)
Affinity DataIC50: 21nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199011BDBM199011(US9221832, 75)
Affinity DataIC50: 22nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198968BDBM198968(US9221832, 32)
Affinity DataIC50: 23nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199059BDBM199059(US9221832, 123)
Affinity DataIC50: 23nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199054BDBM199054(US9221832, 118)
Affinity DataIC50: 24nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199049BDBM199049(US9221832, 113)
Affinity DataIC50: 28nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199034BDBM199034(US9221832, 98)
Affinity DataIC50: 29nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198964BDBM198964(US9221832, 28)
Affinity DataIC50: 29nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199043BDBM199043(US9221832, 107)
Affinity DataIC50: 31nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198937BDBM198937(US9221832, 1)
Affinity DataIC50: 33nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199022BDBM199022(US9221832, 86)
Affinity DataIC50: 33nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199072BDBM199072(US9221832, 137)
Affinity DataIC50: 37nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199082BDBM199082(US9221832, 147)
Affinity DataIC50: 40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198940BDBM198940(US9221832, 4)
Affinity DataIC50: 40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199035BDBM199035(US9221832, 99)
Affinity DataIC50: 40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199061BDBM199061(US9221832, 125)
Affinity DataIC50: 41nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198939BDBM198939(US9221832, 3)
Affinity DataIC50: 42nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199027BDBM199027(US9221832, 91)
Affinity DataIC50: 42nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199068BDBM199068(US9221832, 133)
Affinity DataIC50: 43nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198944BDBM198944(US9221832, 8)
Affinity DataIC50: 43nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199062BDBM199062(US9221832, 126)
Affinity DataIC50: 45nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199079BDBM199079(US9221832, 144)
Affinity DataIC50: 50nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199056BDBM199056(US9221832, 120)
Affinity DataIC50: 50nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199036BDBM199036(US9221832, 100)
Affinity DataIC50: 52nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199063BDBM199063(US9221832, 127)
Affinity DataIC50: 52nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 199042BDBM199042(US9221832, 106)
Affinity DataIC50: 52nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 198975BDBM198975(US9221832, 39)
Affinity DataIC50: 54nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

Displayed 1 to 50 (of 152 total ) | Next | Last >>
Jump to: